Global Liquid Biopsy By Sampling Type (Blood Sampling LB, Urine Sampling LB and Saliva and Other Tissue Fluids Sampling LB), Products and Service (Assays Kits, Instruments and Services), Circulating Biomarker (Circulating Tumour Cells, Circulating Tumour DNA (CTDNA), Cell-Free DNA, Extracellular Vesicles (EVS) and Other Circulating Biomarkers), Clinical Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring and Recurrence Monitoring), Application (Cancer Applications and Non-Cancer Applications), End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centres and Other End Users), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028
Data Bridge Market Research analyses that the liquid biopsy market will exhibit a CAGR of around 20.28% for the forecast period of 2021-2028. Rising demand for minimally invasive surgeries around the globe, increased focus of technological advancements involved in the manufacturing of medical devices, and rising expenditure on the healthcare infrastructure development especially in the developing economies are the major factors attributable to the growth of liquid biopsy market.
Liquid biopsy is minimally invasive technology wherein test is done on a sample of blood. Liquid biopsy is undertaken to diagnose the cancer cells in the blood that have collectively formed a tumour. A liquid biopsy helps to detect cancer at early stages.
Rising prevalence of cancer among the population is one of the major factors fostering the growth of liquid biopsy market. Rising advent of various innovations and researches in the field of healthcare to integrate technology and rising personal disposable income are some other indirect liquid biopsy market growth determinants. Rising initiatives by the government to spread awareness especially in the developing economies coupled with increasing preference towards non-invasive procedures will further generate lucrative liquid biopsy market growth opportunities.
However, lack awareness in developing and underdeveloped counters will act as a market growth restraint. The low sensitivity and specificity limitations of liquid biopsy will further derail the market growth rate. Unfavourable and unclear regulatory and reimbursement policies especially in the developing economies will further pose challenges for the market.
This liquid biopsy market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on liquid biopsy market contact Data Bridge Market Research for an Analyst Brief; our team will help you take an informed market decision to achieve market growth.
Global Liquid Biopsy Market Scope and Market Size
The liquid biopsy market is segmented on the basis of sampling type, product and service, circulating biomarker, clinical application, application and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- Based on sampling type, the global liquid biopsy market has been divided into blood sampling LB, urine sampling LB and saliva and other tissue fluids sampling LB.
- Based on the products and service, the liquid biopsy market is segmented into assays kits, instruments and services.
- Based on the circulating biomarker, the liquid biopsy market is segmented into circulating tumour cells, circulating tumour DNA (CTDNA), cell-free DNA, extracellular vesicles (EVS) and other circulating biomarkers.
- Based on the clinical application, the liquid biopsy market is segmented into early cancer screening, therapy selection, treatment monitoring and recurrence monitoring.
- Based on the application, the liquid biopsy market is segmented into cancer and non-cancer applications. Cancer application segment is sub-segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer and other cancers.
- Based on the end user, the liquid biopsy market is segmented into reference laboratories, hospitals and physician laboratories, academic and research centres and other end users.
Liquid Biopsy Market Country Level Analysis
The liquid biopsy market is analysed, and market size insights and trends are provided by country, sampling type, product and service, circulating biomarker, clinical application, application and end user as referenced above.
The countries covered in the liquid biopsy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the liquid biopsy market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is because of the prevailing sophisticated level of healthcare facilities coupled with the increasing rate of cancer. Asia-Pacific, on the other hand, is projected to exhibit the highest growth rate during the forecast period owing to the rising demand for non-invasive treatment and increased expenditure on healthcare infrastructure and rising personal disposable income.
The country section of the liquid biopsy market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
Liquid biopsy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for digital health technologies market, impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the liquid biopsy market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Liquid Biopsy Market Share Analysis
The liquid biopsy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to the liquid biopsy market.
The major players covered in the liquid biopsy market report are CareDx, Inc., Eurofins Scientific, MDxHealth., Cardiff Oncology., Immucor, Inc., Thermo Fisher Scientific Inc., Menarini Silicon Biosystems, QIAGEN, Gaurdant Health, Exact Sciences Corporation, Myriad Genetics, Inc., LungLife AI, Inc., Bio-Rad Laboratories, Inc., Natera, Inc., ExoDx, Genomic Health, Inc., Illumina, Inc.,, Biocept, Inc., BGI and F. Hoffmann-La Roche Ltd among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Customization Available : Global Liquid Biopsy Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.